Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung and liver scans could map hidden heart valve disease

NCT ID NCT07042360

Knowledge-focused Sponsor: Prince of Wales Hospital, Shatin, Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are studying how non-invasive tools can characterize tricuspid regurgitation, a heart valve condition linked to heart failure and liver problems. The trial enrolls 450 adults with moderate or worse tricuspid regurgitation and uses a lung fluid sensor and a liver stiffness scanner to measure body fluid and organ changes. By tracking heart failure hospitalizations, valve interventions, and deaths over a year, the team aims to find patterns that predict outcomes and improve treatment planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the approach works, doctors could better predict which patients with tricuspid regurgitation face heart failure hospitalizations or need valve procedures, guiding more personalized treatment.
What could go wrong
This observational study cannot prove cause and effect, and the non-invasive measurements may not reliably capture heart and liver changes in all patients. Results may not apply to those with different heart conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

By analyzing left and right heart function, risk factors, and treatment outcomes, the research aims to phenotype TR using non-invasive assessment tools to predict clinical outcomes and improve treatment strategies for patients with different types of TR.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with \>=moderate TR * able to consent for the study. Exclusion Criteria: 1. LVEF \<=40% 2. Have significant left sided organic valvular heart disease (i.e. \>=moderate AS, \>=moderate MS, \>=moderate MR of organic or mixed aetiology), dysfunctional mitral valve replacement or aortic valve replacement 3. Prior tricuspid valve interventions (eg TriClip, tricuspid valve repair or replacement) (To allow accurate transient elastography) 4. Known hepatocellular carcinoma 5. Known portal vein thrombosis 6. Established liver cirrhosis with a known liver-related aetiology 7. Hepatitis C infection and not on treatment 8. Uncontrolled hepatitis (e.g. hepatitis B infection, autoimmune hepatitis) 9. Fatty liver with evidence of non-alcoholic fatty liver disease or cirrhosis (to allow accurate non-invasive lung fluid assessment) 10. recent rib fracture (\<3 months) with or without flail chest 11. BMI \<20 or \>36 12. Height \<155cm or \>195cm 13. Patients with right lung tumor 14. Patients with right sided pacemaker 15. Patients with known underlying exudative right pleural effusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tricuspid regurgitation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tricuspid regurgitation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Prince of Wales Hospital

    RECRUITING

    Hong Kong, Shatin, 0000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.